Almirall emerges from losses and reaches nearly 1 billion in sales

BarcelonaCatalan pharmaceutical group Almirall turns the page and returns to profit in its 2024 results. The company left losses behind and made a profit of 10.1 million euros compared to the negative 38.5 million in the previous year, it reported in a statement on Monday. The company has explained that its profits were "moderately affected by minor impairments."

The biopharmaceutical company has assured that it exceeded its expectations in terms of sales and gross operating profit (ebitda), thanks to the good performance of the dermatology business in Europe and its portfolio of biological treatments. Specifically, its revenues increased by 10.3%, to 985.7 million euros, while the ebitda reached 192.6 million euros, 10.6% above the previous year.

Medical dermatology products generated the majority of Almirall's revenue, with sales of €548.1 million, up 17.8%. In Europe, the company's dermatology business grew by 22.5% to €484.1 million. "We continue to make progress in our promising business," said Almirall. pipeline [a concept from the pharmaceutical sector to refer to the range of products under investigation and those that are coming on the market] in medical dermatology to invest in the initial and middle phases," said Carlos Gallardo, President and CEO of Almirall.

Almirall completed its generational change at the beginning of 2022, when Carlos Gallardo Piqué took over from his father, Jorge Gallardo, after 34 years at the head of the pharmaceutical company. Gallardo Piqué has also ended up assuming executive functions and the role of CEO, after the Italian Gianfranco Nazzi left the position in November 2022. In 2024, the company reached 80 years of history.

Forecasts for 2025

The Catalan biopharmaceutical company invested 124.2 million euros last year in research and development, which represents 12.6% of sales in 2024. Looking ahead to this new year, the Catalan company expects to increase its revenues by between 10% and 13% and achieve an EBITDA of between 22.

Almirall is particularly optimistic about the performance of two specific products. Ebglyss is a drug containing the active ingredient lebrikizumab and is used to treat atopic dermatitis. The group highlights that in 2024 it has achieved sales of 33.2 million euros, mainly due to the push to Germany, and that it "continues to receive very positive comments from dermatologists." On the other hand, Almirall celebrates the growth of Ilumetrio, a psoriasis treatment containing tildrakizumab, which has achieved a 25.5% increase in sales, reaching 208.8 million, achieving a greater market share compared to the competition.